AnteoTech (ASX: ADO) has reported progress across both its advanced battery technologies and life sciences businesses during the December 2025 quarter, alongside a capital raise that extends its funding runway into calendar year 2026.
The quarter focused on expanding the product sales pipeline and advancing joint development partnerships intended to open new markets and accelerate commercialisation.
AnteoTech said the $3.5 million equity raise completed in January provides the financial capacity to convert existing trials and partnerships into revenue-generating outcomes.
Battery Technologies Gain Momentum
AnteoTech executed a development and sales agreement with US-based Black Diamond Structures to commercialise a combined Anteo X and Molecular Rebar carbon nanotube dispersion product, with initial customer trials scheduled to commence in February 2026.
The company also achieved a tenfold manufacturing scale-up of its Ultranode 70 anode material, with commercial form factor cell evaluations underway with Wyon AG and results expected by the end of March.
Ultranode X reached a new performance milestone of more than 1,000 charge-discharge cycles at 80% capacity retention, improving on the previously reported 990 cycles and strengthening AnteoTech’s position in strategic development discussions.
In parallel, two non-exclusive joint development agreements for Ultranode 95 are under negotiation with battery manufacturers supplying drone makers, while Anteo X continues to be evaluated by a growing number of potential customers.
Life Sciences Business Expands
During the quarter, AnteoTech received a US$185,000 order for AnteoBind from the Serum Institute of India under the parties’ existing five-year supply agreement, with payment received and product despatched in early January.
The company also secured new AnteoBind sales with Japanese customers worth approximately $70,000, reflecting increased market awareness following execution of its June 2025 strategy.
AnteoTech provided samples of a new AnteoBind-activated ELISA plate product to the Serum Institute and is preparing to commence evaluations with additional pharmaceutical and biotechnology customers through its distributor network.
Internal comparative studies showed AnteoBind NXT delivers up to six times lower antibody usage and reduced non-specific binding compared with Tosyl chemistry in chemiluminescent immunoassay applications, with a white paper in preparation.
Sales Growth Initiatives
The $3.5m capital raise, which took place subsequent to quarter end, saw 245.7 million shares placed at $0.0155, along with 1-for-2 attaching listed and unlisted options exercisable at A$0.035.
AnteoTech has earmarked the proceeds to support its sales growth initiatives and strategic partnership development across the business.
The company held cash of $1.4m with no debt as at 31 December 2025, increasing to a pro forma balance of $4.9m following the placement.
Managing director and chief executive officer Merrill Gray said the company’s focus for the quarter had been on the sales pipeline.
“We now have two sales and marketing personnel in Brisbane and are using more structured sales processes,” Ms Gray said.
“This (March) quarter the focus is on sales conversion.”
